Everest Medicines Limited announces that Mr. Bo Tan has resigned as an independent non-executive director of the Company, the chairperson of the remuneration committee and a member of each of the audit committee and nomination committee of the Company with effect from 19 January 2023 to devote more time to his other business endeavours. The Board announces that Ms. Hoi Yam Chui has been appointed as an independent non-executive director of the Company, the chairperson of the remuneration committee and a member of each of the audit committee and nomination committee of the Company with effect from 19 January 2023. The biographical details of Ms. Chui are set out below: Ms. Chui, aged 55, has been an executive director of China Biotech Services Holdings Limited, a company listed on the GEM of the Stock Exchange, since December 2022.

Previously, she was president of Harbin Pharmaceutical Group Co. Ltd. a company listed on the Shanghai Stock Exchange, from March 2019 to May 2022 and a director of Harbin Pharmaceutical from January 2021 to May 2022, where she was responsible for the overall business operation. Ms. Chui has previously also worked in China Hewlett-Packard Co.

Ltd. and Novartis International. Ms. Chui received her bachelor's degree in Economic Administration and master's degree in Finance from Peking University, the People's Republic of China in July 1990 and July 2001, respectively. Following the resignation of Mr. Tan and appointment of Ms. Chui, Mr. Tan has ceased to be the chairperson of the remuneration committee and a member of each of the audit committee and nomination committee of the Company; and Ms. Chui has been appointed as the chairperson of the remuneration committee and a member of each of the audit committee and nomination committee of the Company, with effect from 19 January 2023.